Conclusion. About one in 11 admissions with UTI are ESBL + /FQ NS and are more likely to be male, with HCA risk factors and other important comorbidities. Current oral antibiotic therapy is limited in such episodes and oral treatment alternatives are needed. 5 cfu/mL. UTI-(fever, dysuria, +/− allograft or suprapubic pain) + positive culture. EAB-asymptomatic bacteriuria in the EPT period. rUTI: ≥ 3 UTIs in 1 year or 2 UTIs in 6 consecutive months within the year post-transplant. UTI episodes were considered separate if occurred >3 weeks after completion of prior antibiotics. Data were analyzed by Fischer's exact test and chi-square test.
Association of Antibiotic Treatment Duration with First Recurrence of Uncomplicated Urinary Tract Infection in Pediatric Patients
Titilola M. Afolabi, PharmD, BCPS, BCPPS; Kellie J. Goodlet, PharmD, BCPS and Kathleen A. Fairman, MA; Midwestern University, Glendale, Arizona Session: 150. Urinary Tract Infection Friday, October 5, 2018: 12:30 PM Background. The optimal antibiotic (ABX) treatment duration for uncomplicated urinary tract infection (UTI) in pediatric patients is unknown. The objective of this study was to investigate the association of pediatric UTI treatment duration (7, 10, or 14 days) with infection recurrence or progression.
Methods. A retrospective cohort analysis of pediatric patients aged 2-17 years with first cystitis or pyelonephritis and without renal/anatomic abnormality was performed using claims and eligibility data from Truven Health MarketScan Database for 2013-2015. Parenteral ABX use and treatment of cystitis diagnosis only were covariates. Relapse and reinfection were defined a priori as UTI diagnosed from, respectively, 0-14 days and 15-30 days following ABX depletion; recurrence was defined as either relapse or reinfection. Progressing infection was defined as recurrence diagnosis of pyelonephritis in a patient originally diagnosed with cystitis only.
Results. Of 7,698 pediatric patients (43.8% aged 2-10 years; 56.2% aged 11-17 years), 85.5% had cystitis and 14.3% pyelonephritis. Duration of ABX treatment included: 3-5 days for cystitis only (20.4%), or 7 (33.6%), 10 (44.2%), or 14 (1.8%) days for any UTI. Recurrence and progressing infection occurred in 5.5% and 0.2% of patients, respectively. Covariates associated with increased recurrence risk included pre-treatment ABX exposure (OR = 1.29; 95% CI = 1.06-1.57); pyelonephritis on diagnosis date (OR = 1.44; 95% CI = 1.03-2.00); follow-up visit during ABX treatment (OR = 3.21; 95% CI = 2.20-4.68); parenteral ABX (OR = 1.89, 95% CI = 1.33-2.69); use of nitrofurantoin (NFT) only (OR = 1.34, 95% CI = 1.00-1.92); and interaction of NFT with pyelonephritis diagnosis (OR = 3.68, 95% CI = 1.20-11.29). After adjustment for measured confounders, the association between duration of ABX treatment and recurrence was not significant (compared with 7 days, 10 days: OR = 1.07, 95% CI = 0.85-1.33; compared with 7 days, 14 days: OR = 0.89, 95% CI 0.45-1.78).
Conclusion. In a national cohort of pediatric patients with uncomplicated UTI, rates of recurrence after ABX depletion did not significantly differ among treatment durations of 7, 10, and 14 days. Results provide support for, without definitively establishing efficacy of, shorter-course ABX treatment.
Disclosures. Background. The ED environment makes proactive collection of urine cultures (UCs) favorable. However, unnecessary UCs can result in over-detection and over-treatment of asymptomatic bacteriuria (ASB). A previous analysis at the study facility found that UCs were collected frequently despite negative urinalyses (UA), which commonly resulted in unnecessary antibiotics. Our objective was to compare the frequency of inappropriate UC utilization and inappropriate antibiotic prescribing post implementation of a "Urinalysis to Reflex Culture" process change intervention. A secondary objective was to assess the frequency of health encounters for UTIs post implementation.
Methods. After education, an ED process change was implemented in October 2017. This included automatic UC cancellation if UAs had <5 WBC/HPF. An option for "do not cancel (DNC)" UC was available for specific conditions (eg. pregnancy) per guidelines. Data were prospectively collected for 3 months post-implementation and included UA/UC results, presence of UTI symptoms, antibiotics prescribed and healthcare utilization. Inappropriate UC was defined as a UC ordered despite negative UA in asymptomatic patients. Inappropriate antibiotic prescribing was defined as treatment in patients with ASB. A Student's t-test and contingency tables were applied in SAS; significance was set at P ≤ 0.05.
Results. There were 684 UAs (37.2% post-intervention) evaluated from ED visits. Post-intervention (n = 255 UAs), 37.3% of UAs were negative with UCs cancelled. Of the remaining UAs, 37.3% were positive with a processed UC, 16.9% were ordered as DNC and 8.6% were ordered without a UC. UC processing despite a negative UA significantly decreased from 100% pre-intervention to 38.6% post-intervention (P < 0.001). Inappropriate antibiotics for ASB also decreased from 10.2% pre-intervention to 1.9% post-intervention (OR = 0.17; P < 0.0110). In patients with negative UAs, antibiotic prescribing decreased by 25.3% post-intervention (P = NS). No reports of outpatient, ED, or hospital visits for UTI symptoms were found within 7 days of initial UA post-intervention.
Conclusion.
A "UA to Reflex Culture" process change demonstrated a significant decrease in processing of inappropriate UCs and unnecessary antibiotics for ASB. There were no missed UTIs or other adverse patient outcomes.
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